Gianfranco Ferraccioli

Rationale for T Cell Inhibition by Cyclosporin A in Major Autoimmune Diseases

M. Santis, G. Ferraccioli, P. Tomietto, 2005, Annals of the New York Academy of Sciences.

Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren's syndrome.

C. Avellini, C. Beltrami, A. Carbone, 1997, Arthritis and rheumatism.

The −670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis

R. Abbate, S. Bombardieri, M. Manetti, 2008, Annals of the rheumatic diseases.

Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review.

F. Wolfe, T. Pincus, R. Rau, 2002, Rheumatology.

Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A.

G. Pasero, V. Pipitone, E. Marubini, 1996, Arthritis and rheumatism.

EFFICACY AND SAFETY OF RITUXIMAB IN TYPE II MIXED CRYOGLOBULINEMIA Short title : rituximab therapy in mixed cryoglobulinemia

G. Ferraccioli, S. Sacco, C. Mazzaro, 2003 .

General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus.

S. D'agostini, G. La Torre, S. De Vita, 2007, Arthritis and rheumatism.